• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Transl Myol . . Prospects of plasmapheresis for patients with severe COVID-19

tetano

Editor, Senior Moderator
Eur J Transl Myol


. 2020 Sep 9;30(3):9165.
doi: 10.4081/ejtm.2020.9165. eCollection 2020 Sep 30.
Prospects of plasmapheresis for patients with severe COVID-19


Ilmira R Gilmutdinova[SUP] 1 [/SUP], Maksim Yu Yakovlev[SUP] 1 [/SUP], Petr S Eremin[SUP] 1 [/SUP], Anatoliy D Fesun[SUP] 1 [/SUP]



Affiliations

Abstract

On February 11, 2020, the World Health Organization officially named the infection caused by the new coronavirus "Coronavirus disease 2019" (COVID-19). On February 11, 2020, the International Committee on Taxonomy of Viruses (ICTV) officially named the infectious matter "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2). Emergence of severe complications with new coronavirus disease is due to the development of hypercytokinaemia, also known as "cytokine storm". These complications comprise acute respiratory distress syndrome (ARDS), respiratory failure and death. Emerging data point to the logic of using extracorporeal haemocorrection to normalise cytokine levels and reduce the severity of organ disorders. The analysis of the literature indicates that to date, a certain positive experience has been accumulated in the world in the application of extracorporeal methods in clinical practice in patients with COVID-19.

Keywords: COVID-19; coronavirus; extracorporeal haemocorrection; plasmapheresis.
 
Back
Top Bottom